# Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

> **NCT02276612** · PHASE2,PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 60 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** E/C/F/TAF

## Key facts

- **NCT ID:** NCT02276612
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-03
- **Primary completion:** 2016-11-10
- **Final completion:** 2017-10-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02276612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02276612, "Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02276612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*